Form 4: Boston Scientific Executive Trades BSX Stock
Statement of Changes in Beneficial Ownership
Boston Scientific Corp. executive Padraig Andrew O'Connor reported transactions involving company stock and restricted stock units.
Summary
- Padraig Andrew O'Connor, EVP of Global Operations at Boston Scientific Corp., reported a transaction on May 2, 2026.
- O'Connor acquired 1,802 shares of common stock through the vesting of restricted stock units (RSUs) with no cost basis.
- Following this acquisition, O'Connor beneficially owns 7,896 shares of common stock directly.
- Additionally, O'Connor disposed of 872 shares of common stock for $56.50 per share, resulting in 7,024 shares directly owned.
- The RSUs vest in four equal annual installments starting May 2, 2023.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions related to executive compensation rather than significant strategic shifts or financial performance indicators.
Positives
- Acquisition of 1,802 shares of common stock through RSU vesting indicates continued equity incentive for executive leadership.
- The executive retains a significant number of shares (7,024) after the reported disposal.
Negatives
- Disposal of 872 shares of common stock at $56.50 per share may suggest the executive is diversifying or realizing gains.
Future Outlook
The vesting schedule for restricted stock units indicates a continued commitment to issuing shares over four annual installments, with the first installment having begun on May 2, 2023.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard for tracking insider transactions within the medical device industry, providing transparency on executive stock holdings and trading activities.
Stakeholder Impact
- Shareholders: Increased transparency into executive stock ownership and potential selling pressure from insider sales.
- Employees: Reinforces the equity-based compensation structure for executives.
- Management: Demonstrates adherence to SEC reporting requirements for beneficial ownership changes.
Next Steps
- Continued vesting of restricted stock units over the next annual installments.
- Potential future transactions by the reporting person as per their equity incentive plan.
Key Dates
| Date | Description |
|---|---|
| 05/02/2023 | First anniversary of the date of grant for RSUs, marking the beginning of annual installments. |
| 05/02/2026 | Transaction date for the acquisition of common stock via RSU vesting and disposal of common stock. |
| 05/04/2026 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
Boston Scientific, BSX, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Stock Options, SEC Filing, Securities Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.